JPRN-UMIN000022819招募中未知
Clinical research on sequential combination therapy with CHOP and mogamulizumab in patients with untreated primary adult T cell leukemia-lymphoma (FBMTG MOG16) - FBMTG MOG16
Cooperative research with Fukuoka Blood & Marrow Transplant Group and CReS Kyushu0 个研究点目标入组 30 人开始时间: 2016年6月21日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with uncontrollable diabetes mellitus. 2) Patients with uncontrollable hypertension. 3) Patients with uncontrollable autoimmune disease. 4) Patients with severe skin disorder other than ATL lesion. 5) Patients with anamnesis of myocardial infarction and congestive heart failure, and complication of unstable angina. 6) Patients with less than 50% of resting ejection fraction in echocardiography and nuclear medical scan. 7) Patients with active double cancer. 8) Patients with uncontrollable active infection. 9) Patients with central nervous infiltration. 10) Patients with HIV antibody positive or HBs antigen positive. 11) Patients with complication of mental disease or psychiatric symptom. 12) Patients with pregnancy or possibility of pregnancy and patients with nursing. 13) Patients judged by the investigator to be inappropriate for study participation.
研究者
相似试验
尚未招募
不适用
A clinical study on efficacy of combination therapy of triptan agent and anti-epileptic drug in patients with severe migraine seizuresMigraineJPRN-UMIN000029846Tokyo Women's Medical University110
已完成
2 期
Sequential combination therapy with CHOP and mogamulizumab in untreated primary ATLL patientsadult T-cell leukemia-lymphomaJPRN-jRCTs071180057Kato Koji24
进行中（未招募）
不适用
Pilot study - sequential combination therapy using selective immunoglobulin apheresis and omalizumab in patients with severe atopic dermatitis and elevated total IgE levelsPatients with severe Atopic dermatitis and total IgE-level > 700 IU/ml (potentially associated with bronchial asthma and/or allergic rhinitis)MedDRA version: 12.0Level: LLTClassification code 10002198Term: Anaphylactic reactionMedDRA version: 12.0Level: LLTClassification code 10040400Term: Serum sicknessMedDRA version: 12.0Level: LLTClassification code 10043554Term: ThrombocytopeniaMedDRA version: 12.0Level: LLTClassification code 10019211Term: HeadacheMedDRA version: 12.0Level: LLTClassification code 10028810Term: NasopharyngitisMedDRA version: 12.0Level: LLTClassification code 10040753Term: SinusitisMedDRA version: 12.0Level: LLTClassification code 10022000Term: InfluenzaMedDRA version: 12.0Level: LLTClassification code 10006451Term: BronchitisMedDRA version: 12.0Level: LLTClassification code 10017888Term: GastroenteritisMedDRA version: 12.0Level: LLTClassification code 10034835Term: PharyngitisMedDRA version: 12.0Level: LLTClassification code 10047461Term: Viral infectionMedDRA version: 12.0Level: LLTClassification code 10034844Term: Pharyngolaryngeal painMedDRA version: 12.0Level: LLTClassification code 10011224Term: CoughMedDRA version: 12.0Level: LLTClassification code 10039083Term: RhinitisMedDRA version: 12.0Level: LLTClassification code 10028735Term: Nasal congestionMedDRA version: 12.0Level: LLTClassification code 10039085Term: Rhinitis allergicMedDRA version: 12.0Level: LLTClassification code 10012727Term: DiarrheaMedDRA version: 12.0Level: LLTClassification code 10028813Term: NauseaMedDRA version: 12.0Level: LLTClassification code 10013946Term: DyspepsiaMedDRA version: 12.0Level: LLTClassification code 10003988Term: Back painMedDRA version: 12.0Level: LLTClassification code 10003239Term: ArthralgiaMedDRA version: 12.0Level: LLTClassification code 10028411Term:EUCTR2009-014582-51-DEFaculty of Medicine, Technische Universität München
进行中（未招募）
不适用
Efficacy and safety study of a sequential therapy of tocilizumab (TCZ) and, if initially inade-quately responded to tocilizumab (TCZ), followed by rituximab (RTX) in DMARD-IR patients with rheumatoid arthritis (MIRAI) - MIRAIEUCTR2010-022049-88-DERoche Pharma AG
尚未招募
不适用
Examination of effectiveness of combination therapy of periodontal tissue regeneration drug Regroth and bone substitute material for periodontal tissue regeneratioPeriodontal DiseaseJPRN-UMIN000034480Tokushima University Hospital80